Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E H Gerlach

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Diagnostic Microbiology and Infectious Disease|April 1, 1986
In vitro activity of DJ-6783 (a keto carboxylic acid) compared with six other orally administered antimicrobial agentsR N Jones, L W Ayers, A L Barry, et al.
The Journal of Antimicrobial Chemotherapy|October 7, 2009
Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility testsR N Jones, A L Barry, C Thornsberry, et al.
Diagnostic Microbiology and Infectious Disease|March 1, 1987
CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteriaP C Fuchs, A L Barry, R N Jones, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1980
Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testingP C Fuchs, A L Barry, C Thornsberry, et al.
Journal of Clinical Microbiology|January 1, 1992
MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycinM J Bale, R N Jones, M E Erwin, et al.
Diagnostic Microbiology and Infectious Disease|January 1, 1988
Effect of clavulanic acid on the susceptibility of clinical anaerobic bacteria to ticarcillin: a multicenter studyP C Fuchs, R N Jones, A L Barry, et al.
Journal of Clinical Microbiology|March 1, 1992
Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycinM J Bale, R N Jones, M E Erwin, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 1, 1988
In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101A L Barry, K E Aldridge, S D Allen, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1989
Multicenter in vitro evaluation of SM-7338, a new carbapenemR N Jones, K E Aldridge, S D Allen, et al.
Diagnostic Microbiology and Infectious Disease|August 1, 1993
In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centersH S Sader, R N Jones, J A Washington, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Diagnostic Microbiology and Infectious Disease|April 1, 1986
In vitro activity of DJ-6783 (a keto carboxylic acid) compared with six other orally administered antimicrobial agentsR N Jones, L W Ayers, A L Barry, et al.
The Journal of Antimicrobial Chemotherapy|October 7, 2009
Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility testsR N Jones, A L Barry, C Thornsberry, et al.
Diagnostic Microbiology and Infectious Disease|March 1, 1987
CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteriaP C Fuchs, A L Barry, R N Jones, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1980
Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testingP C Fuchs, A L Barry, C Thornsberry, et al.
Journal of Clinical Microbiology|January 1, 1992
MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycinM J Bale, R N Jones, M E Erwin, et al.
Diagnostic Microbiology and Infectious Disease|January 1, 1988
Effect of clavulanic acid on the susceptibility of clinical anaerobic bacteria to ticarcillin: a multicenter studyP C Fuchs, R N Jones, A L Barry, et al.
Journal of Clinical Microbiology|March 1, 1992
Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycinM J Bale, R N Jones, M E Erwin, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 1, 1988
In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101A L Barry, K E Aldridge, S D Allen, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1989
Multicenter in vitro evaluation of SM-7338, a new carbapenemR N Jones, K E Aldridge, S D Allen, et al.
Diagnostic Microbiology and Infectious Disease|August 1, 1993
In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centersH S Sader, R N Jones, J A Washington, et al.
Pageof 9